Kobayashi Pharmaceutical Co., Ltd. (TYO:4967)
Japan · Delayed Price · Currency is JPY | Market Cap | 434.81B +6.3% |
| Revenue (ttm) | 166.80B +3.1% |
| Net Income | 3.07B -71.4% |
| EPS | 41.27 -71.4% |
| Shares Out | 74.34M |
| PE Ratio | 141.72 |
| Forward PE | 37.65 |
| Dividend | 106.00 (1.82%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | 197,100 |
| Average Volume | 198,095 |
| Open | 5,849.00 |
| Previous Close | 5,849.00 |
| Day's Range | 5,810.00 - 5,930.00 |
| 52-Week Range | 4,850.00 - 6,140.00 |
| Beta | 0.26 |
| RSI | 48.74 |
| Earnings Date | May 8, 2026 |
About Kobayashi Pharmaceutical
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sh... [Read more]
Financial Performance
In 2025, Kobayashi Pharmaceutical's revenue was 165.74 billion, an increase of 0.09% compared to the previous year's 165.60 billion. Earnings were 3.66 billion, a decrease of -63.68%.
Financial StatementsNews
Kobayashi Pharmaceutical upgraded to Hold from Underperform at Jefferies
Jefferies analyst Hisae Kawamoto upgraded Kobayashi Pharmaceutical (KBYPF) to Hold from Underperform with an unchanged price target of 4,900 yen. The pace of increase in the number of people affected
Kobayashi Pharmaceutical initiated with an Underperform at Jefferies
Jefferies initiated coverage of Kobayashi Pharmaceutical with an Underperform rating and 4,800 yen price target. The analyst initiated coverage on 11 stocks in the Japan cosmetics and toiletries secto...